ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
부갑상선 기능 저하증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.3%로 성장할 전망이며, 14억 2,000만 달러로 성장이 예측됩니다. 예측 기간 중의 성장은 유전자 재조합 부갑상선 호르몬 요법 채용 증가, 부갑상선 기능 저하증 조사에 대한 투자 증가, 헬스케어 인프라의 확대, 내분비 장애에 취약한 고령자 인구의 증가, 인지도 향상 및 조기 진단에 대한 대처에 기인하고 있습니다. 이 기간 주요 동향으로는 부갑상선 호르몬 요법의 발전, 부갑상선 기능 저하증의 진단 기술의 향상, 서방성 칼슘 보충제의 개발, 저침습 갑상선 수술의 혁신, 환자 모니터링 기술의 진보 등을 들 수 있습니다.
갑상선암의 이환율의 상승이 향후 수년간 부갑상선 기능 저하증 시장의 성장을 견인할 것으로 예측됩니다. 갑상선암은 갑상선의 비정상적인 세포 증식을 특징으로 하는 암의 일종이며, 종종 경부에 덩어리를 가져옵니다. 갑상선암 환자의 증가는 무증상의 작은 갑상선 결절을 더 빨리, 더 자주 발견할 수 있게 된 화상 진단 기술의 진보에 기인하고 있습니다. 갑상선암은 의도치 않게 부갑상선을 손상시킬 수 있는 갑상선 수술의 수를 늘림으로써 부갑상선 기능 저하증에 기여하고 있습니다. 이 손상은 칼슘의 불균형과 만성적인 호르몬 결핍으로 이어져 장기적인 질병관리 솔루션의 수요를 끌어올립니다. 예를 들어 2024년 5월 미국 비영리단체인 미국암협회는 갑상선암 신규 사례 수가 2023년 4만 3,720명에서 2025년 4만4,020명에 이를 것으로 예측된다고 보고했습니다. 이처럼 갑상선암 사례의 증가가 부갑상선 기능 저하증 시장의 확대를 뒷받침하고 있습니다.
부갑상선 기능 저하증 시장의 주요 기업은 치료 효과를 높이고 환자의 예후를 개선하기 위해 TransCon 기술을 기반으로 한 제품 등 기술적으로 선진적인 제품의 개발에 주력하고 있습니다. TransCon(Transient Conjugation) 기술은 약물 전달을 최적화하기 위해 설계된 자체 플랫폼입니다. 예를 들어 2024년 1월 덴마크에 거점을 둔 바이오의약품회사 Ascendis Pharma A/S는 TransCon 기술을 이용한 두 번째 제품인 YORVIPATH(palopegteriparatide)를 성인의 만성 부갑상선 기능저하증 치료제로 독일과 오스트리아에서 출시했습니다. YORVIPATH는 1일 1회 투여하는 부갑상선 호르몬(PTH 1-34)의 프로드럭으로 24시간에 걸쳐 생리적인 PTH 수준을 유지하도록 설계되었으며 만성 부갑상선 기능저하증의 뿌리에 있는 호르몬 결핍증에 효과적으로 대처합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 부갑상선 기능 저하증 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 부갑상선 기능 저하증 시장 : 성장률 분석
세계의 부갑상선 기능 저하증 시장 실적 : 규모 및 성장(2019-2024년)
세계의 부갑상선 기능 저하증 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 부갑상선 기능 저하증 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 부갑상선 기능 저하증 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
호르몬 보충 요법
보조요법
세계의 부갑상선 기능 저하증 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
호르몬 보충 요법
칼슘과 비타민 D의 보충 교재
신흥 치료법
세계의 부갑상선 기능 저하증 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
비경구
세계의 부갑상선 기능 저하증 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 부갑상선 기능 저하증 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
재택 케어 설정
세계의 부갑상선 기능 저하증 시장 : 호르몬 보충 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
재조합 부갑상선 호르몬
부갑상선 호르몬 유사체
칼슘 자극제
칼슘 및 비타민 D의 보충 교재
세계의 부갑상선 기능 저하증 시장 : 보조 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
마그네슘 보충제
인산 결합제
기타 지지요법
제7장 지역별 및 국가별 분석
세계의 부갑상선 기능 저하증 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 부갑상선 기능 저하증 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
부갑상선 기능 저하증 시장 : 경쟁 구도
부갑상선 기능 저하증 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Novartis AG
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Cipla Limited
Lupin Limited
Torrent Pharmaceuticals Ltd.
Eagle Pharmaceuticals Inc.
BridgeBio Pharma Inc.
Ascendis Pharma A/S
Extend Biosciences Inc.
Entera Bio Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
부갑상선 기능 저하증 시장(2029년) : 새로운 기회를 제공하는 국가
부갑상선 기능 저하증 시장(2029년) : 새로운 기회를 제공하는 부문
부갑상선 기능 저하증 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH) by the parathyroid glands, resulting in low calcium and high phosphorus levels in the blood. The main role of parathyroid hormone (PTH) is to regulate and maintain stable calcium and phosphorus levels, which are vital for nerve, muscle, and bone function. Hypoparathyroidism may occur due to surgical removal or damage to the parathyroid glands, autoimmune diseases, genetic disorders, or, in rare cases, unknown causes.
The primary treatments for hypoparathyroidism include hormone replacement therapy and adjunctive therapies. Hormone replacement therapy (HRT) involves administering hormones to replace or supplement those that the body no longer produces adequately. Treatment options include hormone replacement therapy, calcium and vitamin D supplements, and emerging therapies. These treatments are administered through oral or parenteral routes and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, serving various end users such as hospitals, specialty clinics, and homecare settings.
The hypoparathyroidism market research report is one of a series of new reports from The Business Research Company that provides hypoparathyroidism market statistics, including hypoparathyroidism industry global market size, regional shares, competitors with hypoparathyroidism market share, hypoparathyroidism market segments, market trends and opportunities, and any further data you may need to thrive in the hypoparathyroidism industry. This hypoparathyroidism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hypoparathyroidism market size has grown strongly in recent years. It will grow from $0.95 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the rising number of thyroid surgeries, increased awareness of hypoparathyroidism, a rise in postoperative complications, growing demand for calcium and vitamin D supplements, and heightened focus on managing endocrine disorders.
The hypoparathyroidism market size is expected to see strong growth in the next few years. It will grow to $1.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth during the forecast period can be attributed to the increasing adoption of recombinant parathyroid hormone therapies, rising investment in hypoparathyroidism research, expansion of healthcare infrastructure, a growing geriatric population vulnerable to endocrine disorders, and enhanced awareness and early diagnosis efforts. Key trends in this period include advancements in parathyroid hormone therapies, improved diagnostic techniques for hypoparathyroidism, development of sustained-release calcium supplements, innovations in minimally invasive thyroid surgery, and progress in patient monitoring technologies.
The rising incidence of thyroid cancer is expected to drive the growth of the hypoparathyroidism market in the coming years. Thyroid cancer is a type of cancer characterized by abnormal cell growth in the thyroid gland, often resulting in a lump in the neck. The increase in thyroid cancer cases is attributed to advancements in diagnostic imaging technologies, which allow for earlier and more frequent detection of small, asymptomatic thyroid nodules. Thyroid cancer contributes to hypoparathyroidism by increasing the number of thyroid surgeries, which can unintentionally damage the parathyroid glands. This damage leads to calcium imbalances and chronic hormone deficiency, boosting the demand for long-term disease management solutions. For example, in May 2024, the American Cancer Society, a US-based non-profit organization, reported that new thyroid cancer cases were projected to reach 44,020 in 2025, up from 43,720 in 2023. Thus, the growing number of thyroid cancer cases is fueling the expansion of the hypoparathyroidism market.
Leading companies in the hypoparathyroidism market are concentrating on developing technologically advanced products, such as those based on TransCon technology, to enhance treatment effectiveness and improve patient outcomes. TransCon (Transient Conjugation) technology is a proprietary platform designed to optimize drug delivery. For example, in January 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched YORVIPATH (palopegteriparatide), its second product utilizing TransCon technology, in Germany and Austria for treating adults with chronic hypoparathyroidism. YORVIPATH is a once-daily prodrug of parathyroid hormone (PTH 1-34) engineered to maintain physiological PTH levels over 24 hours, effectively addressing the hormone deficiency underlying chronic hypoparathyroidism.
In July 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Amolyt Pharma SAS for an undisclosed sum. Through this acquisition, AstraZeneca intends to bolster its rare disease portfolio, especially within endocrine disorders, by leveraging Amolyt Pharma's innovative pipeline and clinical-stage therapies. Amolyt Pharma SAS, based in France, is a biotechnology firm developing eneboparatide, a long-acting parathyroid hormone analog for hypoparathyroidism treatment.
Major players in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc , Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited , Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.
North America was the largest region in the hypoparathyroidism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypoparathyroidism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hypoparathyroidism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hypoparathyroidism market consists of revenues earned by entities by providing services such as diagnostic testing, patient monitoring, telemedicine consultations, and specialized care for chronic disease management and education. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoparathyroidism market also includes sales of phosphate binders, and medical devices or diagnostic kits used for monitoring calcium, phosphorus, and parathyroid Hormone levels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hypoparathyroidism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hypoparathyroidism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hypoparathyroidism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypoparathyroidism market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Hormone Replacement Therapy; Adjunctive Therapies
2) By Type: Hormone Replacement Therapy; Calcium And Vitamin D Supplements; Emerging Therapies
3) By Route Of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End User: Hospitals; Specialty Clinics; Homecare Settings
Subsegments:
1) By Hormone Replacement Therapy: Recombinant Parathyroid Hormone; Parathyroid Hormone Analogues; Calcimimetics; Calcium And Vitamin D Supplements
2) By Adjunctive Therapies: Magnesium Supplements; Phosphate Binders; Other Supportive Therapies
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co Inc.; AbbVie Inc.; Sanofi S.A.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Hypoparathyroidism Market Characteristics
3. Hypoparathyroidism Market Trends And Strategies
4. Hypoparathyroidism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Hypoparathyroidism Growth Analysis And Strategic Analysis Framework
5.1. Global Hypoparathyroidism PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hypoparathyroidism Market Growth Rate Analysis
5.4. Global Hypoparathyroidism Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hypoparathyroidism Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hypoparathyroidism Total Addressable Market (TAM)
6. Hypoparathyroidism Market Segmentation
6.1. Global Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hormone Replacement Therapy
Adjunctive Therapies
6.2. Global Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hormone Replacement Therapy
Calcium And Vitamin D Supplements
Emerging Therapies
6.3. Global Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.4. Global Hypoparathyroidism Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.5. Global Hypoparathyroidism Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare Settings
6.6. Global Hypoparathyroidism Market, Sub-Segmentation Of Hormone Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Parathyroid Hormone
Parathyroid Hormone Analogues
Calcimimetics
Calcium And Vitamin D Supplements
6.7. Global Hypoparathyroidism Market, Sub-Segmentation Of Adjunctive Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Magnesium Supplements
Phosphate Binders
Other Supportive Therapies
7. Hypoparathyroidism Market Regional And Country Analysis
7.1. Global Hypoparathyroidism Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hypoparathyroidism Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hypoparathyroidism Market
9.1. China Hypoparathyroidism Market Overview
9.2. China Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hypoparathyroidism Market
10.1. India Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hypoparathyroidism Market
11.1. Japan Hypoparathyroidism Market Overview
11.2. Japan Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hypoparathyroidism Market
12.1. Australia Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hypoparathyroidism Market
13.1. Indonesia Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hypoparathyroidism Market
14.1. South Korea Hypoparathyroidism Market Overview
14.2. South Korea Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hypoparathyroidism Market
15.1. Western Europe Hypoparathyroidism Market Overview
15.2. Western Europe Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hypoparathyroidism Market
16.1. UK Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Hypoparathyroidism Market
17.1. Germany Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hypoparathyroidism Market
18.1. France Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Hypoparathyroidism Market
19.1. Italy Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Hypoparathyroidism Market
20.1. Spain Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hypoparathyroidism Market
21.1. Eastern Europe Hypoparathyroidism Market Overview
21.2. Eastern Europe Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hypoparathyroidism Market
22.1. Russia Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hypoparathyroidism Market
23.1. North America Hypoparathyroidism Market Overview
23.2. North America Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hypoparathyroidism Market
24.1. USA Hypoparathyroidism Market Overview
24.2. USA Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Hypoparathyroidism Market
25.1. Canada Hypoparathyroidism Market Overview
25.2. Canada Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hypoparathyroidism Market
26.1. South America Hypoparathyroidism Market Overview
26.2. South America Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hypoparathyroidism Market
27.1. Brazil Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hypoparathyroidism Market
28.1. Middle East Hypoparathyroidism Market Overview
28.2. Middle East Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hypoparathyroidism Market
29.1. Africa Hypoparathyroidism Market Overview
29.2. Africa Hypoparathyroidism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hypoparathyroidism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hypoparathyroidism Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hypoparathyroidism Market Competitive Landscape And Company Profiles
